SCHEMBL30633802

SCHEMBL30633802

CCOC(=O)c1c(C)c(=O)c2ccc(B3OC(C)(C)C(C)(C)O3)cc2n1C(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UCHL1 P09936 1/20 0.39
ATM Q13315 1/20 0.36
CSF1R P07333 1/20 0.36
PRMT5 O14744 2/20 0.36
WDR77 Q9BQA1 2/20 0.36
HIF1A Q16665 2/20 0.34
MAPT P10636 3/20 0.33
GAA P10253 1/20 0.33
LIPG Q9Y5X9 2/20 0.32
AKR1B1 P15121 1/20 0.32
AAK1 Q2M2I8 1/20 0.32
PTGER4 P35408 1/20 0.32
RARA P10276 1/20 0.32
RARB P10826 1/20 0.32
ROCK1 Q13464 1/20 0.32
LPL P06858 1/20 0.32
ALDH1A1 P00352 1/20 0.32
RECQL P46063 1/20 0.32
PKM P14618 1/20 0.32
IRAK4 Q9NWZ3 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30633689 0.83 AKR1B1 (0.37) UCHL1ATMCSF1RPRMT5WDR77
SCHEMBL30633732 0.79 LMNA (0.46) ATMMAPTGAAALDH1A1
SCHEMBL26613892 0.79 LMNA (0.46) ATMMAPTGAAALDH1A1
SCHEMBL12997511 0.76 LMNA (0.43) CSF1RHIF1AMAPTROCK1ALDH1A1
SCHEMBL20045112 0.74 LPL (0.41) CSF1RPRMT5WDR77LIPGLPL
SCHEMBL30633762 0.72 CSF1R (0.38) CSF1RPRMT5WDR77LIPGROCK1
SCHEMBL30633741 0.72 PRMT5 (0.39) CSF1RPRMT5WDR77HIF1ALIPG
SCHEMBL31558780 0.72 PRMT5 (0.41) CSF1RPRMT5WDR77MAPTGAA
SCHEMBL17206078 0.72 PARG (0.47) CSF1RHIF1AMAPT
SCHEMBL31257749 0.71 PRMT5 (0.34) CSF1RPRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136586-A1 Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors BEIGENE, LTD. (KY) 2025-05-01 US disclosed
EP-4514797-A1 SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS BeiGene, Ltd. (KY) 2025-03-05 EP disclosed
WO-2023208172-A1 SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS BEIGENE , LTD. (KY) 2023-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136586-A1 Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors CDK4, CDK7, CDK8 UCHL1 4295/4885ATM 406/4885CSF1R 3194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.